Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph node metastases
The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash position
CAESAREA, Israel, Aug. 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2026 before the Nasdaq Stock Market opens on Wednesday, August 12, 2026. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day.
Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization
Published in the International Journal of Surgery, globally ranked in the top three among surgery journals, the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients
CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor, for the purchase and sale of 1,833,334 ordinary shares (or ordinary share equivalents in lieu thereof), Series D Warrants to purchase up to 1,833,334 ordinary shares (the "Series D Warrants") and Series E Warrants to purchase up to 1,833,334 ordinary shares (the "Series E Warrants," and together with the Series D Warrants, the "Warrants") at a combined purchase price of $3.00 per share and accompanying Warrants in a private placement, priced at a premium to the previous Nasdaq closing price for the Company's ordinary shares. The gross proceeds from the offering are expected to be approximately $5.5 million, before deducting placement agent commissions and other estimated offering expenses. The Warrants will have an exercise price of $3.00 per share and will be exercisable immediately upon issuance. The Series D Warrants will expire five years following the date of issuance and the Series E Warrants will expire one year following the date of issuance.
Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences compared to last year
